PwC Estimates 200,000 Indian Households Use GLP-1 Drugs for Diabetes and Obesity
A PwC report estimates that around 200,000 Indian households use GLP-1 drugs like Ozempic and Mounjaro to manage diabetes and obesity, with many users concentrated in major metropolitan areas. Monthly spending per household ranges from Rs 8,000 to 16,000. The market is growing rapidly, doubling annually, driven by high prevalence of related health conditions. A PwC survey also found that while 97% of respondents prioritize long-term well-being, 67% face barriers such as stress and fatigue in maintaining healthy lifestyles.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 38/100.
Outlets measured: moneycontrol, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 17 Nov, 11:17 am. Other outlets followed.
